Luca Grattarola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luca Grattarola has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andi Nuredini
Department of Biomedical, Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy
1 shared publication - Anna Odone
Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy
1 shared publication - Giuseppe Dantona
Criams-Sport Medicine Centre Voghera, University of Pavia
1 shared publication - Matteo Fortunati
Centro di Ricerca Interdipartimentale Attività Motorie e Sportive (CRIAMS)-Sport Medicine Centre Voghera, University of Pavia, 27058 Voghera, Italy
1 shared publication - Oscar Crisafulli
Centro di Ricerca Interdipartimentale Attività Motorie e Sportive (CRIAMS)-Sport Medicine Centre Voghera, University of Pavia, 27058 Voghera, Italy
1 shared publication - Renato Baptista
Department of Research and Development, LUNEX, Differdange, Luxembourg
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (5) , 1443-1449
Whole Body Phase Angle as a Promising Marker of Disease Severity in Facioscapulohumeral Muscular Dystrophy
Introduction/Aims: To investigate its potential role as a marker of disease severity in facioscapulohumeral dystrophy (FSHD), this study examined the association between whole‐body phase angle (PhA) and clinically assessed severity in FSHD patients. Methods: Patients were evaluated for PhA using bioelectrical impedance analysis ( BIA ) and for disease severity using the FSHD clinical score. In a subgroup, physical activity level ( PAL ) was assessed using a questionnaire. Pearson correlations were performed in the total cohort and PAL ‐assessed subgroup, stratified by sex and clinical phenotype (category A and non‐A) according to the Comprehensive Clinical Evaluation Form. Multivariate regression analyses were conducted adjusting for age, body mass index, and PAL . Due to the small sample, correlation was not performed in PAL ‐assessed non‐A patients, while multivariate regression was not performed in non‐A patients and PAL ‐assessed stratified subgroups. Results: Seventy‐two patients (mean age 39.94 ± 17.52 years; 27 females and 45 males; 58 category A and 14 non‐A) were enrolled. The PAL ‐assessed subgroup comprised 38 patients (mean age 41.39 ± 14.98 years; 16 females and 22 males; 31 category A and 7 non‐A). Pearson analyses revealed that PhA was inversely associated with clinical score in all groups ( r –0.63 to –0.84, p 0.02 to < 0.001). Multivariate regression confirmed PhA as the sole independent predictor across all groups ( β = –0.64 to –0.93, all p < 0.001). Discussion: These results support the potential role of PhA as a marker of disease severity in FSHD . Longitudinal studies are warranted to determine its sensitivity for monitoring disease progression over time.
- 31 August 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (5) , 1443-1449
Open AccessWhole Body Phase Angle as a Promising Marker of Disease Severity in Facioscapulohumeral Muscular Dystrophy
Introduction/Aims: To investigate its potential role as a marker of disease severity in facioscapulohumeral dystrophy (FSHD), this study examined the association between whole‐body phase angle (PhA) and clinically assessed severity in FSHD patients. Methods: Patients were evaluated for PhA using bioelectrical impedance analysis ( BIA ) and for disease severity using the FSHD clinical score. In a subgroup, physical activity level ( PAL ) was assessed using a questionnaire. Pearson correlations were performed in the total cohort and PAL ‐assessed subgroup, stratified by sex and clinical phenotype (category A and non‐A) according to the Comprehensive Clinical Evaluation Form. Multivariate regression analyses were conducted adjusting for age, body mass index, and PAL . Due to the small sample, correlation was not performed in PAL ‐assessed non‐A patients, while multivariate regression was not performed in non‐A patients and PAL ‐assessed stratified subgroups. Results: Seventy‐two patients (mean age 39.94 ± 17.52 years; 27 females and 45 males; 58 category A and 14 non‐A) were enrolled. The PAL ‐assessed subgroup comprised 38 patients (mean age 41.39 ± 14.98 years; 16 females and 22 males; 31 category A and 7 non‐A). Pearson analyses revealed that PhA was inversely associated with clinical score in all groups ( r –0.63 to –0.84, p 0.02 to < 0.001). Multivariate regression confirmed PhA as the sole independent predictor across all groups ( β = –0.64 to –0.93, all p < 0.001). Discussion: These results support the potential role of PhA as a marker of disease severity in FSHD . Longitudinal studies are warranted to determine its sensitivity for monitoring disease progression over time.